|
HNRNPH3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.30150334953782E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.885400E-01 |
| Stage1-vs-Stage3 |
6.381900E-03 |
| Stage1-vs-Stage4 |
1.759330E-04 |
| Stage2-vs-Stage3 |
5.303800E-01 |
| Stage2-vs-Stage4 |
1.420000E-01 |
| Stage3-vs-Stage4 |
2.919200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
4.52570000031294E-07 |
| Normal-vs-Asian |
5.58299961816999E-10 |
| Caucasian-vs-AfricanAmerican |
4.402000E-01 |
| Caucasian-vs-Asian |
9.967600E-02 |
| AfricanAmerican-vs-Asian |
6.712000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
2.683600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
4.49219999998363E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.275010E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.409200E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.289420E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.633800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.006400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.058400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.628900E-04 |
| Classical-VS-Follicular |
1.517630E-01 |
| Classical-VS-Other |
9.926800E-01 |
| Classical-VS-Normal |
5.1716408933089E-12 |
| Tall-VS-Follicular |
3.002000E-02 |
| Tall-VS-Other |
2.204600E-01 |
| Tall-VS-Normal |
6.66133814775094E-16 |
| Follicular-VS-Other |
6.552000E-01 |
| Follicular-VS-Normal |
3.83959530836364E-12 |
| Other-VS-Normal |
3.078600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.87738713464114E-13 |
| N0-vs-N1 |
5.300200E-01 |
|
|
